Gilead Sciences, Inc. (GILD) Shares Bought by Balasa Dinverno & Foltz LLC
Balasa Dinverno & Foltz LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 22,319 shares of the biopharmaceutical company’s stock after buying an additional 3,311 shares during the period. Balasa Dinverno & Foltz LLC’s holdings in Gilead Sciences were worth $1,808,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in GILD. Contrarius Investment Management Ltd raised its holdings in Gilead Sciences by 2,630.1% during the 1st quarter. Contrarius Investment Management Ltd now owns 904,865 shares of the biopharmaceutical company’s stock worth $61,458,000 after buying an additional 871,721 shares during the period. Heritage Trust Co acquired a new stake in Gilead Sciences during the 1st quarter worth approximately $3,589,000. Pitcairn Co. raised its holdings in Gilead Sciences by 37.1% during the 1st quarter. Pitcairn Co. now owns 19,231 shares of the biopharmaceutical company’s stock worth $1,306,000 after buying an additional 5,207 shares during the period. Bienville Capital Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $570,000. Finally, Norinchukin Bank The grew its stake in shares of Gilead Sciences by 4.2% during the 1st quarter. Norinchukin Bank The now owns 174,400 shares of the biopharmaceutical company’s stock worth $11,845,000 after acquiring an additional 7,070 shares in the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $75.57 on Monday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market cap of $98,690.00, a price-to-earnings ratio of 7.89, a P/E/G ratio of -1.27 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the business earned $2.75 earnings per share. The firm’s revenue was down 13.2% on a year-over-year basis. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.75%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock valued at $37,404,139 over the last three months. 1.30% of the stock is owned by company insiders.
Several brokerages have recently weighed in on GILD. Leerink Swann raised their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday. Berenberg Bank reaffirmed a “buy” rating and set a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and an average target price of $85.11.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.